Krupa Kansara

Dec 9, 2024 | biorxiv.org | Payal Vaswani |Krupa Kansara |Ashutosh Kumar |Dhiraj D Bhatia

AbstractParkinsons disease is one of the neuropathies characterized by accumulation of alpha-synuclein protein, leading to motor dysfunction. Levodopa is the gold standard treatment, however, in long term usage, it leads to levodopa induced dyskinesia (LID). New therapeutic options are need of the hour to treat the alpha-synuclein based neuropathies. The role of imbalance of neurotransmitters other than dopamine has been underestimated in alpha-synuclein based neuropathies.

May 6, 2023 | biorxiv.org | Ramesh Singh |Pankaj Yadav |Ashutosh Kumar |Krupa Kansara

Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.